Polivy
What Polivy is used for
Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Polivy
- Active substance
- polatuzumab vedotin
- Disease area
- Lymphoma, B-Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX14
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2020
Official information
In the USA
Same active substance: Polivy
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Polivy used for?
Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
What is the active substance in Polivy?
Polivy contains polatuzumab vedotin.
Who makes Polivy?
The EU marketing authorisation holder is Roche Registration GmbH.
Is Polivy an orphan medicine?
Yes. Polivy is designated an orphan medicine in the EU, for a rare disease (Lymphoma, B-Cell).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU